OptimizeRx (OPRX) was upgraded by Zacks Research from "hold" to "strong-buy".
OptimizeRx: Q4 Earnings Report Indicates Caution For 2026 [Seeking Alpha]
OptimizeRx Corp (OPRX) Q4 2025 Earnings Call Highlights: Strong Revenue Growth and Strategic ... [Yahoo! Finance]
OptimizeRx (OPRX) had its price target lowered by Lake Street Capital from $24.00 to $20.00. They now have a "buy" rating on the stock.
OptimizeRx (OPRX) had its price target lowered by Roth Mkm from $32.00 to $18.00. They now have a "buy" rating on the stock.